The U.S. Food and Drug Administration has issued a complete response letter for AstraZeneca’s subcutaneous injection therapy for systemic lupus erythematosus, citing deficiencies in the pivotal Phase III data package related to patient subgroup consistency and long-term safety biomarkers. AstraZeneca has agreed a regulatory roadmap with the agency to address the issues by submitting additional immunogenicity analyses and extending follow-up on renal function markers. A final decision on the resubmitted application is expected in the first half of 2026.

AstraZeneca has entered an eight-program collaboration with China’s CSPC Pharmaceutical Group to co-develop and commercialize a once-monthly injectable weight-management portfolio. Under the agreement, AZN secures global rights outside Greater China and will lead late-stage clinical development for two lead candidates projected to address a combined peak annual revenue opportunity exceeding $5 billion. The deal includes milestone payments totaling up to $600 million and tiered royalties in the mid-teens on net sales.

As of January 31, 2026, AstraZeneca ordinary shares began direct trading on the New York Stock Exchange, aligning its listing with the London Stock Exchange and Nasdaq Stockholm under a single ticker. This move replaces the prior American Depositary Receipt structure on Nasdaq and broadens access for U.S. institutional and retail investors. AstraZeneca’s Chair highlighted that last year’s pipeline readouts represented over $10 billion of future revenue potential, reinforcing confidence in the company’s ambition to reach $80 billion in annual sales by 2030 and launch 20 new medicines over the same period.